title: [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD].
abstract: Attention Deficit Hyperactivity Disorder (ADHD) is not only a childhood disorder but symptoms persist into adolescence and adulthood in approximately one third of the patients. Especially inattention and poor concentration impair driving performance in road traffic. Adolescents and young adults with ADHD are twice as likely to be involved in traffic accidents as people of the same age. This review sums up the legal situation in Germany and provides an overview of the current existing experimental studies on driving performance of adolescents and young adults with ADHD. Psychostimulant therapy seems to improve driving performance in ADHD patients. At the same time psychostimulants are prohibited, according to the road traffic act. Atomoxetine as a non-stimulant is not mentioned there. Therefore it could be unproblematically prescribed, however, the evidence for improved driving is not as unequivocal as for methylphenidate. The psychoeducation of adolescents and young adults with ADHD concerning their increased risk in road traffic often seems to be insufficient in clinical practice. Given the high number of traffic deaths in these young age groups consulting regarding this matter should be of high priority.
authors.affiliation: Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Universitätsklinikum Ulm, Ulm. andrea.ludolph@uni-ulm.de
authors.forename: Andrea G
authors.initials: AG
authors.lastname: Ludolph
authors.forename: Michael
authors.initials: M
authors.lastname: Kölch
authors.forename: Paul L
authors.initials: PL
authors.lastname: Plener
authors.forename: Ulrike M
authors.initials: UM
authors.lastname: Schulze
authors.forename: Nina
authors.initials: N
authors.lastname: Spröber
authors.forename: Jörg M
authors.initials: JM
authors.lastname: Fegert
mesh_terms: D000063:Accidents, Traffic / Q000331:legislation & jurisprudence* / Q000517:prevention & control; D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000662:Amphetamines / Q000009:adverse effects / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001288:Attention / Q000187:drug effects; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D015813:Substance Abuse Detection / Q000331:legislation & jurisprudence; D055815:Young Adult
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000662:Amphetamines; D000697:Central Nervous System Stimulants; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride